Prognostic evaluation of COX-2 expression in renal cell carcinoma

Anticancer Research

Volumn 30, Issue 7, 2010, Pages 3023-3030

  Kankuri Tammilehto, Minna K ^a   Söderström, Karl Ove ^a   Pelliniemi, Tarja Terttu ^a   Vahlberg, Tero ^b   Pyrhönen, Seppo O ^a   Salminen, Eeva K ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b Turku University   (Finland)

Author keywords

Cyclooxygenase 2; Ki 67; Metastases; Renal cell carcinoma; Survival

Indexed keywords

ALPHA INTERFERON; CYCLOOXYGENASE 2; KI 67 ANTIGEN; PROTEIN P53; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; CYTOPLASM; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; KIDNEY CARCINOMA; KIDNEY METASTASIS; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADULT; AGED; CARCINOMA, RENAL CELL; CELL MEMBRANE; CYCLOOXYGENASE 2; CYTOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77955820652     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics 2002. CA Cancer J Clin 55(2): 74-108, 2005.
2. McNichols DW, Segura JW and DeWeerd: Renal cell carcinoma: Long-term survival and late recurrence. J Urol 126: 17-22, 1981.
3. Choueiri TK, Rini B, Garcia JA, Baz RC, Abou-Jawde RM, Thakkar SG, Elson P, Mekhail TM, Zhou M and Bukowski RM: Prognostic factors associated with long-term survival in previously untreated metastatic renal cell carcinoma. Ann Oncol 18(2): 249-255, 2007.
4. Kankuri M, Pelliniemi TT, Pyrhönen S, Nikkanen V, Helenius H and Salminen E: Feasibility of prolonged use of interferon-α in metastatic kidney carcinoma. A phase II study. Cancer 92: 761-767, 2001.
5. Donskov F and von der Maase H: Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J Clin Oncol 24(13): 1997-2005, 2006.
6. Larkin JM, Chowdhury S and Gore ME: Drug insight: advances in renal cell carcinoma and the role of targeted therapies. Nat Clin Pract Oncol 4: 470-479, 2007. (Pubitemid 47393803)
7. Robson CJ, Churchill BM and Anderson W: The results of radical nephrectomy for renal carcinoma (1969). J Urol 167: 873-875, 2002.
8. Kankuri M, Söderström KO, Pelliniemi TT, Vahlberg T, Pyrhönen S and Salminen E: The association of immunoreactive p53 and Ki-67 with T-stage, grade, occurrence of metastases and survival in renal cell carcinoma. Anticancer Res 26(5B): 3825-3233, 2006.
9. Négrier S, Escudier B, Gomez F, Douillard JY, Ravaud A, Chevreau C, Buclon M, Pérol D and Lasset C: Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie. Ann Oncol 13(9): 1460-1468, 2002.
10. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A and Ferrara J: Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17(5): 2530-2540, 1999.
11. Uhlman DL, Nguyen PL, Manivel JC, Aeppli D, Resnick JM, Fraley EE, Zhang G and Niehans GA: Association of immunohistochemical staining for p53 with metastatic progression and poor survival in patients with renal cell carcinoma. J Natl Cancer Inst 56: 1470-1475, 1994. (Pubitemid 24317590)
12. Taketo MM: Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J Natl Cancer Inst 90: 1529-1536, 1998.
13. Mungan MU, Gurel D, Canda AE, Tuna B, Yorukoglu K and Kirkali Z: Expression of COX-2 in normal and pyelonephritic kidney, renal intraepithelial neoplasia, and renal cell carcinoma. Eur Urol 50(1): 92-97, 2006.
14. Yoshimura R, Matsuyama M, Kawahito Y, Tsuchida K, Kuratsukuri K, Takemoto Y, Mitsuhashi M, Sano H and Nakatani T: Study of cyclooxygenase-2 in renal cell carcinoma. Int J Mol Med 13(2): 229-233, 2004.
15. Elinq TE, Thompson DC, Foureman GL, Curtis JF and Hughes MF: Prostaglandin H synthase and xenobiotic oxidation. Ann Rev Pharmacol Toxicol 30: 1-45, 1990.
16. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, Edwards DA, Flickinger AG, Moore RJ and Seibert K.: Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 60: 1306-1311, 2000.
17. Tsujii M and DuBois RN: Alterations in cellular adehesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83: 493-501, 1995.
18. Ceccarelli C, Piazzi G, Paterini P, Pantaleo MA, Taffurelli M, Santini D, Martinelli GN and Biasco G: Concurrent EGFR and COX-2 expression in colorectal cancer: proliferation impact and tumour spreading. Ann Oncol 16(Suppl 4): 74-79, 2005.
19. Ristimäki A, Nieminen O, Saukkonen K, Hotakainen K, Nordling S and Haglund C: Expression of cyclooxygenase-2 in human transitional cell carcinoma of the urinary bladder. Am J Pathol 158(3): 849-853, 2001. (Pubitemid 32221778)
20. Miyata Y, Koga S, Kanda S, Nishikido M, Hayashi T and Kanetake H: Expression of cyclooxygenase-2 in renal cell carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, expression of matrix metalloproteinase-2, and survival. Clin Cancer Res 9(5): 1741-1749, 2003.
21. Miller AB, Hoogstraten B, Staquet M and Winkler A: Reporting results of cancer treatment. Cancer 47(1): 207-214, 1981.
22. Kovacs G, Akhtar M, Beckwith BJ, Bugert P, Cooper CS, Delahunt B, Eble JN, Fleming S, Ljungberg B, Medeiros LJ, Moch H, Reuter VE, Ritz E, Roos G, Schmidt D, Srigley JR, Störkel S, van den Berg E and Zbar B: The Heidelberg Classification of renal cell tumors. J Pathol 183: 131-133, 1997.
23. nd edition. Berlin Heidelberg: Springer 1-117, 1998.
24. th edition. New York: John Wiley & Sons, 2002.
25. Rini BI, Weinberg V, Dunlap S, Elchinoff A, Yu N, Bok R, Simko J and Small EJ: Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma. Cancer 106(3): 566-575, 2006. (Pubitemid 43157619)
26. Hemmerlein B, Galuschka L, Putzer N, Zischkau S and Heuser M: Comparative analysis of COX-2, vascular endothelial growth factor and microvessel density in human renal cell carcinomas. Histopathology 45(6): 603-611, 2004. (Pubitemid 40029820)
27. Tuna B, Yorukoglu K, Gurel D, Mungan U and Kirkali Z: Significance of COX-2 expression in human renal cell carcinoma. Urology 64(6): 1116-1120, 2004. (Pubitemid 39647051)
28. nd edition. New York: John Wiley & Sons Inc 1-375, 2000.
29. Khan KNM, Stanfield KM, Trajkovic D and Knapp DW: Expression of cyclooxygenase-2 in canine renal cell carcinoma. Vet Pathol 35: 116-119, 2001. (Pubitemid 33621682)
30. Chen Q, Shinohara N, Abe T, Watanabe T, Nonomura K and Koyanagi T: Significance of COX-2 expression in human renal cell carcinoma cell lines. Int J Cancer 105(6): 825-832, 2004. (Pubitemid 38112609)
31. Cho DS, Joo HJ, Oh DK, Kang JH, Kim YS, Lee KB and Kim SJ: Cyclooxygenase-2 and p53 expression as prognostic indicators in conventional renal cell carcinoma. Yonsei Med J 46(1): 133-140, 2005. (Pubitemid 40372883)
32. Hashimoto Y, Kondo Y, Kimura G, Matsuzawa I, Sato S, Ishizaki M, Imura N, Akimoto M and Hara S: Cyclooxygenase-2 expression and relationship to tumour progression in human renal cell carcinoma. Histopathology 44(4): 353-359, 2004. (Pubitemid 38491302)
33. Hernberg M, Turunen JP, Muhonen T and Pyrhönen S: Tumor-infiltrating lymphocytes in patients with metastatic melanoma receiving chemoimmunotherapy. J Immunother 20(6): 488-495, 1997.
34. Salminen E, Kankuri M, Nuutila J, Lilius EM and Pellimiemi TT: Modulation of IgG and complement receptor expression of phagocytes in kidney cancer patients during treatment with interferon-alpha. Anticancer Res 21(3B): 2049-2055, 2001. (Pubitemid 32728950)
35. Ristimäki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, Joensuu H and Isola J: Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 62(3): 632-635, 2002. (Pubitemid 34126931)
36. DuBois RN and Smalley WE: Cyclooxygenase, NSAIDs, and colorectal cancer. J Gastroenterol 31(6): 898-906, 1996.
37. Maaser K, Däubler P, Barthel B, Heine B, von Lampe B, Stein H, Hoffmeister B, Scherer H and Scherübl H: Oesophageal squamous cell neoplasia in head and neck cancer patients: upregulation of COX-2 during carcinogenesis. Br J Cancer 88(8): 1217-1222, 2003. (Pubitemid 36606336)
38. Han SL, Tang HJ, Hua YW, Ji SQ and Lin DX: Expression of COX-2 in stomach cancers and its relation to their biological features. Dig Surg 20(2): 107-114, 2003.
39. Shirahama T: Cyclooxygenase-2 expression is up-regulated in transitional cell carcinoma and its preneoplastic lesions in the human urinary bladder. Clin Cancer Res 6(6): 2424-2430, 2000.
40. Ranelletti FO, Almadori G, Rocca B, Ferrandina G, Ciabattoni G, Habib A, Galli J, Maggiano N, Gessi M and Lauriola L: Prognostic significance of cyclooxygenase-2 in laryngeal squamous cell carcinoma. Int J Cancer 95(6): 343-349, 2001. (Pubitemid 33015102)